391 related articles for article (PubMed ID: 24041335)
21. Proximity-Dependent Biotinylation and Identification of Flagellar Proteins in Trypanosoma cruzi.
Won MM; Baublis A; Burleigh BA
mSphere; 2023 Jun; 8(3):e0008823. PubMed ID: 37017578
[TBL] [Abstract][Full Text] [Related]
22. Metabolomics, lipidomics and proteomics profiling of myoblasts infected with Trypanosoma cruzi after treatment with different drugs against Chagas disease.
Hennig K; Abi-Ghanem J; Bunescu A; Meniche X; Biliaut E; Ouattara AD; Lewis MD; Kelly JM; Braillard S; Courtemanche G; Chatelain E; Béquet F
Metabolomics; 2019 Aug; 15(9):117. PubMed ID: 31440849
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial disfunction and ROS production are essential for anti-Trypanosoma cruzi activity of β-lapachone-derived naphthoimidazoles.
Bombaça ACS; Viana PG; Santos ACC; Silva TL; Rodrigues ABM; Guimarães ACR; Goulart MOF; da Silva Júnior EN; Menna-Barreto RFS
Free Radic Biol Med; 2019 Jan; 130():408-418. PubMed ID: 30445126
[TBL] [Abstract][Full Text] [Related]
24. Crystal violet structural analogues identified by in silico drug repositioning present anti-Trypanosoma cruzi activity through inhibition of proline transporter TcAAAP069.
Sayé M; Gauna L; Valera-Vera E; Reigada C; Miranda MR; Pereira CA
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007481. PubMed ID: 31961864
[TBL] [Abstract][Full Text] [Related]
25. Anti-Trypanosoma cruzi activity of nicotinamide.
Soares MB; Silva CV; Bastos TM; Guimarães ET; Figueira CP; Smirlis D; Azevedo WF
Acta Trop; 2012 May; 122(2):224-9. PubMed ID: 22281243
[TBL] [Abstract][Full Text] [Related]
26. Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery.
MacLean LM; Thomas J; Lewis MD; Cotillo I; Gray DW; De Rycker M
PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006612. PubMed ID: 30001347
[TBL] [Abstract][Full Text] [Related]
27. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives.
Wilkinson SR; Bot C; Kelly JM; Hall BS
Curr Top Med Chem; 2011; 11(16):2072-84. PubMed ID: 21619510
[TBL] [Abstract][Full Text] [Related]
28. Structural modelling and comparative analysis of homologous, analogous and specific proteins from Trypanosoma cruzi versus Homo sapiens: putative drug targets for chagas' disease treatment.
Capriles PV; Guimarães AC; Otto TD; Miranda AB; Dardenne LE; Degrave WM
BMC Genomics; 2010 Oct; 11():610. PubMed ID: 21034488
[TBL] [Abstract][Full Text] [Related]
29. A decade of targets and patented drugs for chemotherapy of Chagas disease.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):216-59. PubMed ID: 21824073
[TBL] [Abstract][Full Text] [Related]
30. Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model.
Valle-Reyes JS; Melnikov V; Dobrovinskaya O; Rodriguez-Hernández A; Wookee-Zea C; Pimientel-Rodrigez V; Rueda-Valdovinos G; Delgado-Enciso I; López-Lemus UA; Espinoza-Gómez F
Exp Parasitol; 2017 Jan; 172():44-50. PubMed ID: 28011170
[TBL] [Abstract][Full Text] [Related]
31. Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds.
Salas-Sarduy E; Niemirowicz GT; José Cazzulo J; Alvarez VE
Curr Med Chem; 2019; 26(36):6672-6686. PubMed ID: 31284853
[TBL] [Abstract][Full Text] [Related]
32. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
[TBL] [Abstract][Full Text] [Related]
33. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.
Moraes CB; Giardini MA; Kim H; Franco CH; Araujo-Junior AM; Schenkman S; Chatelain E; Freitas-Junior LH
Sci Rep; 2014 Apr; 4():4703. PubMed ID: 24736467
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic screening approaches for Chagas disease drug discovery.
Chatelain E; Ioset JR
Expert Opin Drug Discov; 2018 Feb; 13(2):141-153. PubMed ID: 29235363
[TBL] [Abstract][Full Text] [Related]
35. Anti-T. cruzi agents: our experience in the evaluation of more than five hundred compounds.
Cerecetto H; González M
Mini Rev Med Chem; 2008 Nov; 8(13):1355-83. PubMed ID: 18991753
[TBL] [Abstract][Full Text] [Related]
36. Ergosterol biosynthesis and drug development for Chagas disease.
Urbina JA
Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():311-8. PubMed ID: 19753490
[TBL] [Abstract][Full Text] [Related]
37. Differential Gel Electrophoresis (DIGE) Evaluation of Naphthoimidazoles Mode of Action: A Study in Trypanosoma cruzi Bloodstream Trypomastigotes.
Brunoro GV; Faça VM; Caminha MA; Ferreira AT; Trugilho M; de Moura KC; Perales J; Valente RH; Menna-Barreto RF
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004951. PubMed ID: 27551855
[TBL] [Abstract][Full Text] [Related]
38.
Trevisan RO; Santos MM; Desidério CS; Alves LG; de Jesus Sousa T; de Castro Oliveira L; Jaiswal AK; Tiwari S; Bovi WG; de Oliveira-Silva M; Costa-Madeira JC; Castellano LRC; Silva MV; Azevedo V; Rodrigues Junior V; Oliveira CJF; de Castro Soares S
Dis Markers; 2020; 2020():9130719. PubMed ID: 33488847
[TBL] [Abstract][Full Text] [Related]
39. The ubiquinone synthesis pathway is a promising drug target for Chagas disease.
Nara T; Nakagawa Y; Tsuganezawa K; Yuki H; Sekimata K; Koyama H; Ogawa N; Honma T; Shirouzu M; Fukami T; Matsuo Y; Inaoka DK; Kita K; Tanaka A
PLoS One; 2021; 16(2):e0243855. PubMed ID: 33539347
[TBL] [Abstract][Full Text] [Related]
40. Phenotypic diversity and drug susceptibility of Trypanosoma cruzi TcV clinical isolates.
Quebrada Palacio LP; González MN; Hernandez-Vasquez Y; Perrone AE; Parodi-Talice A; Bua J; Postan M
PLoS One; 2018; 13(9):e0203462. PubMed ID: 30183775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
